179 related articles for article (PubMed ID: 22911710)
1. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
Wang E; Zhao Y; Monaco A; Uccellini L; Kirkwood JM; Spyropoulou-Vlachou M; Panelli MC; Marincola FM; Gogas H
PLoS One; 2012; 7(7):e40805. PubMed ID: 22911710
[TBL] [Abstract][Full Text] [Related]
2. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.
Tarhini AA; Lin Y; Zahoor H; Shuai Y; Butterfield LH; Ringquist S; Gogas H; Sander C; Lee S; Agarwala SS; Kirwood JM
PLoS One; 2015; 10(7):e0132745. PubMed ID: 26192408
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
[TBL] [Abstract][Full Text] [Related]
4. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
Gogas H; Kirkwood JM; Falk CS; Dafni U; Sondak VK; Tsoutsos D; Stratigos A; Markopoulos C; Pectasides D; Spyropoulou-Vlachou M
Cancer; 2010 Sep; 116(18):4326-33. PubMed ID: 20549830
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.
Anaya DA; Xing Y; Feng L; Huang X; Camacho LH; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Cormier JN
Cancer; 2008 May; 112(9):2030-7. PubMed ID: 18320602
[TBL] [Abstract][Full Text] [Related]
6. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
[No Abstract] [Full Text] [Related]
7. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
Gogas H; Dafni U; Koon H; Spyropoulou-Vlachou M; Metaxas Y; Buchbinder E; Pectasides E; Tsoutsos D; Polyzos A; Stratigos A; Markopoulos C; Panagiotou P; Fountzilas G; Castana O; Skarlos P; Atkins MB; Kirkwood JM
J Transl Med; 2010 Nov; 8():108. PubMed ID: 21044351
[TBL] [Abstract][Full Text] [Related]
9. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
10. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
Mocellin S; Pasquali S; Rossi CR; Nitti D
J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
[TBL] [Abstract][Full Text] [Related]
11. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.
Malczewski A; Marshall A; Payne MJ; Mao L; Bafaloukos D; Si L; Pectasides D; Fountzilas G; Guo J; Gogas H; Middleton MR
Cancer Med; 2016 Jan; 5(1):17-23. PubMed ID: 26645567
[TBL] [Abstract][Full Text] [Related]
12. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
Saad M; Lee SJ; Tan AC; El Naqa IM; Hodi FS; Butterfield LH; LaFramboise WA; Storkus W; Karunamurthy AD; Conejo-Garcia J; Hwu P; Streicher H; Sondak VK; Kirkwood JM; Tarhini AA
J Transl Med; 2022 Jun; 20(1):253. PubMed ID: 35659704
[TBL] [Abstract][Full Text] [Related]
13. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
14. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.
Hofmann MA; Kiecker F; Küchler I; Kors C; Trefzer U
J Cancer Res Clin Oncol; 2011 Mar; 137(3):455-62. PubMed ID: 20454974
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
[TBL] [Abstract][Full Text] [Related]
16. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Lian B; Si L; Cui C; Chi Z; Sheng X; Mao L; Li S; Kong Y; Tang B; Guo J
Clin Cancer Res; 2013 Aug; 19(16):4488-98. PubMed ID: 23833309
[TBL] [Abstract][Full Text] [Related]
17. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
18. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
Ugurel S; Rebmann V; Ferrone S; Tilgen W; Grosse-Wilde H; Reinhold U
Cancer; 2001 Jul; 92(2):369-76. PubMed ID: 11466692
[TBL] [Abstract][Full Text] [Related]
19. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma.
Wagner SN; Rebmann V; Willers CP; Grosse-Wilde H; Goos M
Lancet; 2000 Jul; 356(9225):220-1. PubMed ID: 10963203
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy in melanoma.
Mohr P; Weichenthal M; Hauschild A
Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]